Meta Platforms Inc vs Zimmer Biomet Holdings Inc — how do they compare? Meta Platforms Inc trades at $600.44 (market cap $1.53T), while Zimmer Biomet Holdings Inc trades at $97 (market cap $18.55B). The key difference: Meta Platforms Inc is far larger — about 82.5× Zimmer Biomet Holdings Inc's market cap, and Zimmer Biomet Holdings Inc pays the higher dividend (0.99%). Which is the better fit depends on your goals.
| META | ZBH | |
|---|---|---|
Market Cap | $1.53T | $18.55B |
Volume | 24,093,972 | — |
Sector | Media | Health |
52-Week High | $790.00 | $107.71 |
52-Week Low | $525.72 | $79.58 |
Enterprise Value | $1.55T | $25.61B |
Dividend Yield | 0.35% | 0.99% |
Signals from Pluang's Aura AI — not financial advice
Meta Platforms trades at $594.92, up 0.48% with strong fundamentals including 81.75% gross margins and 29.84% net income margin. Recent Q1 2026 earnings beat expectations ($10.44 vs $6.70), though Q2 2026 missed ($6.18 vs $7.19). Technical indicators show bearish signals with current price near pivot point resistance at $598. The company maintains robust cash flow generation of $115.8B from operations in 2025.
Analyst consensus remains strongly bullish with 79% buy ratings and $761.95 price target, representing 28% upside. Key catalysts include AI leadership with Muse Spark launch and strong revenue growth trajectory. Risks include regulatory lawsuits, high capital expenditures, and competitive pressures in social media and AI markets.
No Aura AI signal available yet.
Trailing returns across standard periods
Latest headlines on both assets
Meta Platforms Inc., doing business as Meta and previously known as Facebook Inc. It's a company that acts as a parent platform for Facebook, Messenger, Instagram, Whatsapp, Oculus and other subsidiaries. Among these platforms, Facebook is the number one social media platform in terms of the number of active users.
Read more on META →Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →